

1 AN ACT relating to controlled substances.

2 ***Be it enacted by the General Assembly of the Commonwealth of Kentucky:***

3 ➔Section 1. KRS 218A.010 is amended to read as follows:

4 As used in this chapter:

- 5 (1) "Administer" means the direct application of a controlled substance, whether by
6 injection, inhalation, ingestion, or any other means, to the body of a patient or
7 research subject by:
- 8 (a) A practitioner or by his or her authorized agent under his or her immediate
9 supervision and pursuant to his or her order; or
- 10 (b) The patient or research subject at the direction and in the presence of the
11 practitioner;
- 12 (2) "Anabolic steroid" means any drug or hormonal substance chemically and
13 pharmacologically related to testosterone that promotes muscle growth and includes
14 those substances ***classified as Schedule III controlled substances pursuant to***
15 ***Section 2 of this Act***~~[listed in KRS 218A.090(5)]~~ but does not include estrogens,
16 progestins, and anticosteroids;
- 17 (3) "Cabinet" means the Cabinet for Health and Family Services;
- 18 (4) "Child" means any person under the age of majority as specified in KRS 2.015;
- 19 (5) "Cocaine" means a substance containing any quantity of cocaine, its salts, optical
20 and geometric isomers, and salts of isomers;
- 21 (6) "Controlled substance" means methamphetamine, or a drug, substance, or
22 immediate precursor in Schedules I through V and includes a controlled substance
23 analogue;
- 24 (7) (a) "Controlled substance analogue," except as provided in paragraph (b) of this
25 subsection, means a substance:
- 26 1. The chemical structure of which is substantially similar to the structure
27 of a controlled substance in Schedule I or II; and

- 1 2. Which has a stimulant, depressant, or hallucinogenic effect on the
2 central nervous system that is substantially similar to or greater than the
3 stimulant, depressant, or hallucinogenic effect on the central nervous
4 system of a controlled substance in Schedule I or II; or
- 5 3. With respect to a particular person, which such person represents or
6 intends to have a stimulant, depressant, or hallucinogenic effect on the
7 central nervous system that is substantially similar to or greater than the
8 stimulant, depressant, or hallucinogenic effect on the central nervous
9 system of a controlled substance in Schedule I or II.
- 10 (b) Such term does not include:
- 11 1. Any substance for which there is an approved new drug application;
- 12 2. With respect to a particular person, any substance if an exemption is in
13 effect for investigational use for that person pursuant to federal law to
14 the extent conduct with respect to such substance is pursuant to such
15 exemption; or
- 16 3. Any substance to the extent not intended for human consumption before
17 the exemption described in subparagraph 2. of this paragraph takes
18 effect with respect to that substance;
- 19 (8) "Counterfeit substance" means a controlled substance which, or the container or
20 labeling of which, without authorization, bears the trademark, trade name, or other
21 identifying mark, imprint, number, or device, or any likeness thereof, of a
22 manufacturer, distributor, or dispenser other than the person who in fact
23 manufactured, distributed, or dispensed the substance;
- 24 (9) "Dispense" means to deliver a controlled substance to an ultimate user or research
25 subject by or pursuant to the lawful order of a practitioner, including the packaging,
26 labeling, or compounding necessary to prepare the substance for that delivery;
- 27 (10) "Dispenser" means a person who lawfully dispenses a Schedule II, III, IV, or V

1 controlled substance to or for the use of an ultimate user;

2 (11) "Distribute" means to deliver other than by administering or dispensing a controlled
3 substance;

4 (12) "Dosage unit" means a single pill, capsule, ampule, liquid, or other form of
5 administration available as a single unit;

6 (13) "Drug" means:

7 (a) Substances recognized as drugs in the official United States Pharmacopoeia,
8 official Homeopathic Pharmacopoeia of the United States, or official National
9 Formulary, or any supplement to any of them;

10 (b) Substances intended for use in the diagnosis, care, mitigation, treatment, or
11 prevention of disease in man or animals;

12 (c) Substances (other than food) intended to affect the structure or any function of
13 the body of man or animals; and

14 (d) Substances intended for use as a component of any article specified in this
15 subsection.

16 It does not include devices or their components, parts, or accessories;

17 (14) "Good faith prior examination," as used in KRS Chapter 218A and for criminal
18 prosecution only, means an in-person medical examination of the patient conducted
19 by the prescribing practitioner or other health-care professional routinely relied
20 upon in the ordinary course of his or her practice, at which time the patient is
21 physically examined and a medical history of the patient is obtained. "In-person"
22 includes telehealth examinations. This subsection shall not be applicable to hospice
23 providers licensed pursuant to KRS Chapter 216B;

24 (15) "Hazardous chemical substance" includes any chemical substance used or intended
25 for use in the illegal manufacture of a controlled substance as defined in this section
26 or the illegal manufacture of methamphetamine as defined in KRS 218A.1431,
27 which:

- 1 (a) Poses an explosion hazard;
- 2 (b) Poses a fire hazard; or
- 3 (c) Is poisonous or injurious if handled, swallowed, or inhaled;
- 4 (16) "Heroin" means a substance containing any quantity of heroin, or any of its salts,
- 5 isomers, or salts of isomers;
- 6 (17) "Hydrocodone combination product" means a drug with:
- 7 (a) Not more than three hundred (300) milligrams of dihydrocodeinone, or any of
- 8 its salts, per one hundred (100) milliliters or not more than fifteen (15)
- 9 milligrams per dosage unit, with a fourfold or greater quantity of an
- 10 isoquinoline alkaloid of opium; or
- 11 (b) Not more than three hundred (300) milligrams of dihydrocodeinone, or any of
- 12 its salts, per one hundred (100) milliliters or not more than fifteen (15)
- 13 milligrams per dosage unit, with one (1) or more active, nonnarcotic
- 14 ingredients in recognized therapeutic amounts;
- 15 (18) "Immediate precursor" means a substance which is the principal compound
- 16 commonly used or produced primarily for use, and which is an immediate chemical
- 17 intermediary used or likely to be used in the manufacture of a controlled substance
- 18 or methamphetamine, the control of which is necessary to prevent, curtail, or limit
- 19 manufacture;
- 20 (19) "Intent to manufacture" means any evidence which demonstrates a person's
- 21 conscious objective to manufacture a controlled substance or methamphetamine.
- 22 Such evidence includes but is not limited to statements and a chemical substance's
- 23 usage, quantity, manner of storage, or proximity to other chemical substances or
- 24 equipment used to manufacture a controlled substance or methamphetamine;
- 25 (20) "Isomer" means the optical isomer, except *the Cabinet for Health and Family*
- 26 *Services may include the optical, positional, or geometric isomer to classify any*
- 27 *substance pursuant to Section 2 of this Act*~~as used in KRS 218A.050(3) and~~

1 ~~218A.070(1)(d). As used in KRS 218A.050(3), the term "isomer" means the optical,~~
2 ~~positional, or geometric isomer. As used in KRS 218A.070(1)(d), the term "isomer"~~
3 ~~means the optical or geometric isomer];~~

4 (21) "Manufacture," except as provided in KRS 218A.1431, means the production,
5 preparation, propagation, compounding, conversion, or processing of a controlled
6 substance, either directly or indirectly by extraction from substances of natural
7 origin or independently by means of chemical synthesis, or by a combination of
8 extraction and chemical synthesis, and includes any packaging or repackaging of the
9 substance or labeling or relabeling of its container except that this term does not
10 include activities:

11 (a) By a practitioner as an incident to his or her administering or dispensing of a
12 controlled substance in the course of his or her professional practice;

13 (b) By a practitioner, or by his or her authorized agent under his supervision, for
14 the purpose of, or as an incident to, research, teaching, or chemical analysis
15 and not for sale; or

16 (c) By a pharmacist as an incident to his or her dispensing of a controlled
17 substance in the course of his or her professional practice;

18 (22) "Marijuana" means all parts of the plant *Cannabis* sp., whether growing or not; the
19 seeds thereof; the resin extracted from any part of the plant; and every compound,
20 manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin
21 or any compound, mixture, or preparation which contains any quantity of these
22 substances. The term "marijuana" does not include:

23 (a) Industrial hemp as defined in KRS 260.850;

24 (b) The substance cannabidiol, when transferred, dispensed, or administered
25 pursuant to the written order of a physician practicing at a hospital or
26 associated clinic affiliated with a Kentucky public university having a college
27 or school of medicine; or

- 1 (c) For persons participating in a clinical trial or in an expanded access program,
2 a drug or substance approved for the use of those participants by the United
3 States Food and Drug Administration;
- 4 (23) "Medical history," as used in KRS Chapter 218A and for criminal prosecution only,
5 means an accounting of a patient's medical background, including but not limited to
6 prior medical conditions, prescriptions, and family background;
- 7 (24) "Medical order," as used in KRS Chapter 218A and for criminal prosecution only,
8 means a lawful order of a specifically identified practitioner for a specifically
9 identified patient for the patient's health-care needs. "Medical order" may or may
10 not include a prescription drug order;
- 11 (25) "Medical record," as used in KRS Chapter 218A and for criminal prosecution only,
12 means a record, other than for financial or billing purposes, relating to a patient,
13 kept by a practitioner as a result of the practitioner-patient relationship;
- 14 (26) "Methamphetamine" means any substance that contains any quantity of
15 methamphetamine, or any of its salts, isomers, or salts of isomers;
- 16 (27) "Narcotic drug" means any of the following, whether produced directly or indirectly
17 by extraction from substances of vegetable origin, or independently by means of
18 chemical synthesis, or by a combination of extraction and chemical synthesis:
- 19 (a) Opium and opiate, and any salt, compound, derivative, or preparation of
20 opium or opiate;
- 21 (b) Any salt, compound, isomer, derivative, or preparation thereof which is
22 chemically equivalent or identical with any of the substances referred to in
23 paragraph (a) of this subsection, but not including the isoquinoline alkaloids
24 of opium;
- 25 (c) Opium poppy and poppy straw;
- 26 (d) Coca leaves, except coca leaves and extracts of coca leaves from which
27 cocaine, ecgonine, and derivatives of ecgonine or their salts have been

- 1 removed;
- 2 (e) Cocaine, its salts, optical and geometric isomers, and salts of isomers;
- 3 (f) Ecgonine, its derivatives, their salts, isomers, and salts of isomers; and
- 4 (g) Any compound, mixture, or preparation which contains any quantity of any of
- 5 the substances referred to in paragraphs (a) to (f) of this subsection;
- 6 (28) "Opiate" means any substance having an addiction-forming or addiction-sustaining
- 7 liability similar to morphine or being capable of conversion into a drug having
- 8 addiction-forming or addiction-sustaining liability. It does not include, unless
- 9 specifically designated as controlled under Section 2 of this Act~~[KRS 218A.030]~~,
- 10 the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts
- 11 (dextromethorphan). It does include its racemic and levorotatory forms;
- 12 (29) "Opium poppy" means the plant of the species papaver somniferum L., except its
- 13 seeds;
- 14 (30) "Person" means individual, corporation, government or governmental subdivision
- 15 or agency, business trust, estate, trust, partnership or association, or any other legal
- 16 entity;
- 17 (31) "Physical injury" has the same meaning it has in KRS 500.080;
- 18 (32) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing;
- 19 (33) "Pharmacist" means a natural person licensed by this state to engage in the practice
- 20 of the profession of pharmacy;
- 21 (34) "Practitioner" means a physician, dentist, podiatrist, veterinarian, scientific
- 22 investigator, optometrist as authorized in KRS 320.240, advanced practice
- 23 registered nurse as authorized under KRS 314.011, or other person licensed,
- 24 registered, or otherwise permitted by state or federal law to acquire, distribute,
- 25 dispense, conduct research with respect to, or to administer a controlled substance
- 26 in the course of professional practice or research in this state. "Practitioner" also
- 27 includes a physician, dentist, podiatrist, veterinarian, or advanced practice registered

1 nurse authorized under KRS 314.011 who is a resident of and actively practicing in
2 a state other than Kentucky and who is licensed and has prescriptive authority for
3 controlled substances under the professional licensing laws of another state, unless
4 the person's Kentucky license has been revoked, suspended, restricted, or probated,
5 in which case the terms of the Kentucky license shall prevail;

6 (35) "Practitioner-patient relationship," as used in KRS Chapter 218A and for criminal
7 prosecution only, means a medical relationship that exists between a patient and a
8 practitioner or the practitioner's designee, after the practitioner or his or her
9 designee has conducted at least one (1) good faith prior examination;

10 (36) "Prescription" means a written, electronic, or oral order for a drug or medicine, or
11 combination or mixture of drugs or medicines, or proprietary preparation, signed or
12 given or authorized by a medical, dental, chiropody, veterinarian, optometric
13 practitioner, or advanced practice registered nurse, and intended for use in the
14 diagnosis, cure, mitigation, treatment, or prevention of disease in man or other
15 animals;

16 (37) "Prescription blank," with reference to a controlled substance, means a document
17 that meets the requirements of KRS 218A.204 and 217.216;

18 (38) "Presumptive probation" means a sentence of probation not to exceed the maximum
19 term specified for the offense, subject to conditions otherwise authorized by law,
20 that is presumed to be the appropriate sentence for certain offenses designated in
21 this chapter, notwithstanding contrary provisions of KRS Chapter 533. That
22 presumption shall only be overcome by a finding on the record by the sentencing
23 court of substantial and compelling reasons why the defendant cannot be safely and
24 effectively supervised in the community, is not amenable to community-based
25 treatment, or poses a significant risk to public safety;

26 (39) "Production" includes the manufacture, planting, cultivation, growing, or harvesting
27 of a controlled substance;

- 1 (40) "Recovery program" means an evidence-based, nonclinical service that assists
2 individuals and families working toward sustained recovery from substance use and
3 other criminal risk factors. This can be done through an array of support programs
4 and services that are delivered through residential and nonresidential means;
- 5 (41) "Salvia" means *Salvia divinorum* or Salvinorin A and includes all parts of the plant
6 presently classified botanically as *Salvia divinorum*, whether growing or not, the
7 seeds thereof, any extract from any part of that plant, and every compound,
8 manufacture, derivative, mixture, or preparation of that plant, its seeds, or its
9 extracts, including salts, isomers, and salts of isomers whenever the existence of
10 such salts, isomers, and salts of isomers is possible within the specific chemical
11 designation of that plant, its seeds, or extracts. The term shall not include any other
12 species in the genus *salvia*;
- 13 (42) "Second or subsequent offense" means that for the purposes of this chapter an
14 offense is considered as a second or subsequent offense, if, prior to his or her
15 conviction of the offense, the offender has at any time been convicted under this
16 chapter, or under any statute of the United States, or of any state relating to
17 substances classified as controlled substances or counterfeit substances, except that
18 a prior conviction for a nontrafficking offense shall be treated as a prior offense
19 only when the subsequent offense is a nontrafficking offense. For the purposes of
20 this section, a conviction voided under KRS 218A.275 or 218A.276 shall not
21 constitute a conviction under this chapter;
- 22 (43) "Sell" means to dispose of a controlled substance to another person for
23 consideration or in furtherance of commercial distribution;
- 24 (44) "Serious physical injury" has the same meaning it has in KRS 500.080;
- 25 (45) "Synthetic cannabinoids or piperazines" means any chemical compound which is
26 not approved by the United States Food and Drug Administration or, if approved,
27 which is not dispensed or possessed in accordance with state and federal law, that

1 contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1-
2 Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-
3 naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)indole; dexanabinol (HU-211); or any
4 compound in the following structural classes:

5 (a) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole
6 structure with substitution at the nitrogen atom of the indole ring by an alkyl,
7 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
8 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further
9 substituted in the indole ring to any extent and whether or not substituted in
10 the naphthyl ring to any extent. Examples of this structural class include but
11 are not limited to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081,
12 JWH-122, JWH-200, and AM-2201;

13 (b) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole
14 structure with substitution at the nitrogen atom of the indole ring by an alkyl,
15 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
16 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further
17 substituted in the indole ring to any extent and whether or not substituted in
18 the phenyl ring to any extent. Examples of this structural class include but are
19 not limited to JWH-167, JWH-250, JWH-251, and RCS-8;

20 (c) Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with
21 substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
22 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
23 or 2-(4-morpholinyl)ethyl group whether or not further substituted in the
24 indole ring to any extent and whether or not substituted in the phenyl ring to
25 any extent. Examples of this structural class include but are not limited to
26 AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;

27 (d) Cyclohexylphenols: Any compound containing a 2-(3-

1 hydroxycyclohexyl)phenol structure with substitution at the 5-position of the
2 phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl
4 group whether or not substituted in the cyclohexyl ring to any extent.
5 Examples of this structural class include but are not limited to CP 47,497 and
6 its C8 homologue (cannabicyclohexanol);

7 (e) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-
8 naphthyl)methane structure with substitution at the nitrogen atom of the indole
9 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
10 methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not
11 further substituted in the indole ring to any extent and whether or not
12 substituted in the naphthyl ring to any extent. Examples of this structural class
13 include but are not limited to JWH-175, JWH-184, and JWH-185;

14 (f) Naphthoypyrroles: Any compound containing a 3-(1-naphthoypyrrole
15 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl,
16 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
17 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further
18 substituted in the pyrrole ring to any extent and whether or not substituted in
19 the naphthyl ring to any extent. Examples of this structural class include but
20 are not limited to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

21 (g) Naphthylmethylindenes: Any compound containing a 1-(1-
22 naphthylmethyl)indene structure with substitution at the 3-position of the
23 indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
24 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether
25 or not further substituted in the indene ring to any extent and whether or not
26 substituted in the naphthyl ring to any extent. Examples of this structural class
27 include but are not limited to JWH-176;

- 1 (h) Tetramethylcyclopropanoylindoles: Any compound containing a 3-(1-
2 tetramethylcyclopropoyl)indole structure with substitution at the nitrogen
3 atom of the indole ring by an alkyl, haloalkyl, cycloalkylmethyl,
4 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl
5 group, whether or not further substituted in the indole ring to any extent and
6 whether or not further substituted in the tetramethylcyclopropyl ring to any
7 extent. Examples of this structural class include but are not limited to UR-144
8 and XLR-11;
- 9 (i) Adamantoylindoles: Any compound containing a 3-(1-adamantoyl)indole
10 structure with substitution at the nitrogen atom of the indole ring by an alkyl,
11 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
12 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further
13 substituted in the indole ring to any extent and whether or not substituted in
14 the adamantyl ring system to any extent. Examples of this structural class
15 include but are not limited to AB-001 and AM-1248; or
- 16 (j) Any other synthetic cannabinoid or piperazine which is not approved by the
17 United States Food and Drug Administration or, if approved, which is not
18 dispensed or possessed in accordance with state and federal law;
- 19 (46) "Synthetic cathinones" means any chemical compound which is not approved by the
20 United States Food and Drug Administration or, if approved, which is not dispensed
21 or possessed in accordance with state and federal law (not including bupropion or
22 compounds listed under a different schedule) structurally derived from 2-
23 aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or
24 thiophene ring systems, whether or not the compound is further modified in one (1)
25 or more of the following ways:
- 26 (a) By substitution in the ring system to any extent with alkyl, alkylenedioxy,
27 alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further

- 1 substituted in the ring system by one (1) or more other univalent substituents.
2 Examples of this class include but are not limited to 3,4-
3 Methylenedioxcathinone (bk-MDA);
- 4 (b) By substitution at the 3-position with an acyclic alkyl substituent. Examples of
5 this class include but are not limited to 2-methylamino-1-phenylbutan-1-one
6 (buphedrone);
- 7 (c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
8 methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a
9 cyclic structure. Examples of this class include but are not limited to
10 Dimethylcathinone, Ethcathinone, and α -Pyrrolidinopropiophenone (α -PPP);
11 or
- 12 (d) Any other synthetic cathinone which is not approved by the United States
13 Food and Drug Administration or, if approved, is not dispensed or possessed
14 in accordance with state or federal law;
- 15 (47) "Synthetic drugs" means any synthetic cannabinoids or piperazines or any synthetic
16 cathinones;
- 17 (48) "Telehealth" has the same meaning it has in KRS 311.550;
- 18 (49) "Tetrahydrocannabinols" means synthetic equivalents of the substances contained in
19 the plant, or in the resinous extractives of the plant Cannabis, sp. or synthetic
20 substances, derivatives, and their isomers with similar chemical structure and
21 pharmacological activity such as the following:
- 22 (a) Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers;
23 (b) Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and
24 (c) Delta 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers;
- 25 (50) "Traffic," except as provided in KRS 218A.1431, means to manufacture, distribute,
26 dispense, sell, transfer, or possess with intent to manufacture, distribute, dispense,
27 or sell a controlled substance;

1 (51) "Transfer" means to dispose of a controlled substance to another person without
2 consideration and not in furtherance of commercial distribution; and

3 (52) "Ultimate user" means a person who lawfully possesses a controlled substance for
4 his or her own use or for the use of a member of his or her household or for
5 administering to an animal owned by him or her or by a member of his or her
6 household.

7 ➔Section 2. KRS 218A.020 is amended to read as follows:

8 (1) The Cabinet for Health and Family Services shall administer this chapter and may
9 by administrative regulation add substances to or delete or reschedule all
10 substances enumerated in the schedules authorized under~~[set forth in]~~ this chapter.

11 In making a determination regarding a substance, the Cabinet for Health and Family
12 Services may consider the following:

- 13 (a) The actual or relative potential for abuse;
- 14 (b) The scientific evidence of its pharmacological effect, if known;
- 15 (c) The state of current scientific knowledge regarding the substance;
- 16 (d) The history and current pattern of abuse;
- 17 (e) The scope, duration, and significance of abuse;
- 18 (f) The risk to the public health;
- 19 (g) The potential of the substance to produce psychic or physiological dependence
20 liability; and
- 21 (h) Whether the substance is an immediate precursor of a substance already
22 controlled under this chapter.

23 (2) After considering the factors enumerated in subsection (1) of this section, the
24 Cabinet for Health and Family Services may adopt a regulation controlling the
25 substance if it finds the substance has a potential for abuse.

26 (3) (a) If any substance is designated or~~[,]~~ rescheduled~~[, or deleted]~~ as a controlled
27 substance under the federal Controlled Substances Act, the drug shall be

1 considered to be controlled at the state level in the same numerical schedule
2 corresponding to the federal schedule.

3 **(b) Notwithstanding paragraph (a) of this subsection, the Cabinet for Health**
4 **and Family Services may file an amendment to the administrative**
5 **regulations promulgated pursuant to this section to control the substance in**
6 **a more restrictive numerical schedule than the federal schedule. Any**
7 **amendment filed by administrative regulation pursuant to this subsection**
8 **shall be filed with the Legislative Research Commission no later than ninety**
9 **(90) days from publication in the Federal Register of a final order**
10 **designating a substance as a controlled substance or rescheduling a**
11 **controlled substance**~~law and notice thereof is given to the Cabinet for Health~~
12 ~~and Family Services, the Cabinet for Health and Family Services may~~
13 ~~similarly control the substance under this chapter by regulation].~~

14 (4) The Cabinet for Health and Family Services shall exclude any nonnarcotic
15 substance from a schedule if the substance may be lawfully sold over the counter
16 without prescription under the provisions of the Federal Food, Drug and Cosmetic
17 Act, or the Federal Comprehensive Drug Abuse Prevention and Control Act of
18 1970, or the Kentucky Revised Statutes (for the purposes of this section the
19 Kentucky Revised Statutes shall not include any regulations issued thereunder).

20 (5) The Office of Drug Control Policy may request that the Cabinet for Health and
21 Family Services schedule a substance substantially similar to a synthetic
22 cannabinoid or piperazine or a synthetic cathinone. The cabinet shall consider the
23 request utilizing the criteria established by this section and shall issue a written
24 response within sixty (60) days of the scheduling request delineating the cabinet's
25 decision to schedule or not schedule the substance and the basis for the cabinet's
26 decision. The cabinet's response shall be provided to the Legislative Research
27 Commission and shall be a public record.

1 ➔Section 3. KRS 243.100 is amended to read as follows:

2 A natural person shall not become a licensee under KRS 243.020 to 243.670 if he or she:

- 3 (1) (a) Has been convicted of any felony until five (5) years have passed from the
4 date of conviction, release from custody or incarceration, parole, or
5 termination of probation, whichever is later;
- 6 (b) Has been convicted of any misdemeanor ***involving a controlled substance***
7 ***that is*** described ***in or classified pursuant to Section 2 of this Act or***~~under~~
8 KRS~~[218A.050,]~~ ***218A.040,*** 218A.060,~~[218A.070,]~~ 218A.080,~~[218A.090,]~~
9 218A.100, ***or***~~[218A.110,]~~ 218A.120~~[, or 218A.130]~~ in the two (2) years
10 immediately preceding the application;
- 11 (c) Has been convicted of any misdemeanor directly or indirectly attributable to
12 the use of alcoholic beverages in the two (2) years immediately preceding the
13 application;
- 14 (d) Is under the age of twenty-one (21) years;
- 15 (e) Has had any license issued under this statute relating to the regulation of the
16 manufacture, sale, and transportation of alcoholic beverages revoked for cause
17 or has been convicted of a violation of any such statute, until the expiration of
18 two (2) years from the date of the revocation or conviction; or
- 19 (f) Is not a citizen of the United States and has not had an actual, bona fide
20 residence in this state for at least one (1) year before the date on which his or
21 her application for a license is made. This subsection shall not apply to
22 applicants for manufacturers' licenses, to applicants that are corporations
23 authorized to do business in this state, or to persons licensed on March 7,
24 1938.
- 25 (2) A partnership, limited partnership, limited liability company, corporation, or
26 governmental agency shall not be licensed if:
- 27 (a) Each member of the partnership or each of the directors, principal officers, or

1 managers does not qualify under subsection (1)(a), (b), (c), and (d) of this
2 section;

3 (b) It has had any license issued under this statute relating to the regulation of the
4 manufacture, sale, and transportation of alcoholic beverages revoked for cause
5 or has been convicted of a violation of any such statute, until the expiration of
6 two (2) years from the date of the revocation or conviction; or

7 (c) It is a partnership or corporation, if any member of the partnership or any
8 director, manager, or principal officer of the corporation has had any license
9 issued under any statute relating to the regulation of the manufacture, sale, and
10 transportation of alcoholic beverages, revoked for cause or has been convicted
11 of a violation of any such statute, until the expiration of the later of two (2)
12 years from the date of the revocation or two (2) years from the date of
13 conviction.

14 (3) The provisions of subsection (1)(a) and (b) shall apply to anyone applying for a new
15 license under this chapter after July 15, 1998, but shall not apply to those who
16 renew a license that was originally issued prior to July 15, 1998, or an application
17 for a supplemental license where the original license was issued prior to July 15,
18 1998.

19 ➔Section 4. KRS 243.390 is amended to read as follows:

20 (1) In addition to other information as the board may by administrative regulation
21 require, every application for a license under KRS 243.020 to 243.670 shall contain
22 the following information, given under oath:

23 (a) The name, age, Social Security number, address, residence, and citizenship of
24 each applicant;

25 (b) If the applicant is a partner, the name, age, Social Security number, address,
26 residence, and citizenship of each partner and the name and address of the
27 partnership;

- 1 (c) The name, age, Social Security number, address, residence, and citizenship of
2 each person interested in the business for which the license is sought, together
3 with the nature of that interest, and, if the applicant is a corporation, limited
4 partnership company, or limited liability company, the name, age, Social
5 Security number, address, and residence of each officer, director, member,
6 partner, and managerial employee and the citizenship of each, and the state
7 under the laws of which the corporate applicant is incorporated or organized.
8 The department may require the names of all the stockholders and the
9 percentage of stock held by each;
- 10 (d) The premises to be licensed, stating the street and number, if the premises has
11 a street number, and otherwise such a description that will reasonably indicate
12 the location of the premises;
- 13 (e) A statement that neither the applicant nor any other person referred to in this
14 section has been convicted of~~;~~ any misdemeanor directly or indirectly
15 attributable to alcoholic beverages; any violation **involving a controlled**
16 **substance that is described in or classified pursuant to Section 2 of this Act**
17 **or** ~~of~~ KRS~~[218A.050,]~~ **218A.040,** 218A.060,~~[218A.070,]~~ 218A.080,~~[~~
18 ~~218A.090,]~~ 218A.100, **or**~~[218A.110,]~~ 218A.120~~[, or 218A.130]~~ within the
19 two (2) years immediately preceding the application; any felony, within five
20 (5) years from the later of the date of parole or the date of conviction; or
21 providing false information to the department preceding the application; and
22 that the applicant or any other person referred to in this section has not had
23 any license that has been issued to him under any alcoholic beverage statute
24 revoked for cause within two (2) years prior to the date of the application; and
- 25 (f) A statement that the applicant will in good faith abide by every state and local
26 statute, regulation, and ordinance relating to the manufacture, sale, use of, and
27 trafficking in alcoholic beverages.

1 (2) If, after a license has been issued, there is a change in any of the facts required to be
2 set forth in the application, a verified supplemental statement in writing giving
3 notice of the change shall be filed with the board within ten (10) days after the
4 change.

5 (3) In giving any notice or taking any action in reference to a license, the board may
6 rely upon the information furnished in the application or in the supplemental
7 statement connected with the application. This information, as against the licensee
8 or applicant, shall be conclusively presumed to be correct. The information required
9 to be furnished in the application or supplemental statement shall be deemed
10 material in any prosecution for perjury.

11 ➔Section 5. KRS 243.500 is amended to read as follows:

12 Any license issued under KRS 243.020 to 243.670 may be revoked or suspended for the
13 following causes:

14 (1) Conviction of the licensee or his agent or employee for selling any illegal beverages
15 on the licensed premises.

16 (2) Making any false, material statements in an application for a license or
17 supplemental license.

18 (3) Violation of the provisions of KRS 243.670.

19 (4) Conviction of the licensee or any of his clerks, servants, agents, or employees of:

20 (a) Two (2) violations of the terms and provisions of KRS Chapter 241, 243, or
21 244 or any act regulating the manufacture, sale, and transportation of alcoholic
22 beverages within two (2) consecutive years;

23 (b) Two (2) misdemeanors directly or indirectly attributable to the use of
24 intoxicating liquors within two (2) consecutive years; or

25 (c) Any felony.

26 (5) Failure or default of a licensee to pay an excise tax or any part of the tax or any
27 penalties imposed by or under the provisions of any statutes, ordinances, or Acts of

1 Congress relative to taxation, or for a violation of any administrative regulations
2 promulgated by the Department of Revenue made in pursuance thereof.

3 (6) Revocation of any license or permit provided in KRS 243.060, 243.070, 243.600,
4 and 243.610, or granted under any Act of Congress relative to the regulation of the
5 manufacture, sale, and transportation of alcoholic beverages. Any license issued
6 under KRS 243.020 to 243.670 shall be revoked or suspended if the licensee sells
7 the alcoholic beverages at a price in excess of the price set by federal or state
8 regulations.

9 (7) Setting up, conducting, operating, or keeping, on the licensed premises, any
10 gambling game, device, machine, contrivance, lottery, gift enterprise, handbook, or
11 facility for betting or transmitting bets on horse races; or permitting to be set up,
12 conducted, operated, kept, or engaged in, on the licensed premises, any such game,
13 device, machine, contrivance, lottery, gift enterprise, handbook, or facility. This
14 section shall not apply to contests in which eligibility to participate is determined by
15 chance and the ultimate winner is determined by skill and the licensee has no direct
16 interest, or to the sale of lottery tickets sold under the provisions of KRS Chapter
17 154A.

18 (8) Conviction of the licensee, his agents, servants, or employees for:

19 (a) The sale or use upon the licensed premises of those items ***classified pursuant***
20 ***to Section 2 of this Act*** ~~described in KRS 218A.050 to 218A.130~~ as
21 controlled substances, including synthetic drugs;

22 (b) Knowingly permitting the sale or use by patrons upon the licensed premises of
23 those items ***classified pursuant to Section 2 of this Act*** ~~described in KRS~~
24 ~~218A.050 to 218A.130~~ as controlled substances, including synthetic drugs; or

25 (c) Knowingly receiving stolen property upon the licensed premises.

26 ➔Section 6. KRS 314.011 is amended to read as follows:

27 As used in this chapter, unless the context thereof requires otherwise:

- 1 (1) "Board" means Kentucky Board of Nursing;
- 2 (2) "Delegation" means directing a competent person to perform a selected nursing
3 activity or task in a selected situation under the nurse's supervision and pursuant to
4 administrative regulations promulgated by the board in accordance with the
5 provisions of KRS Chapter 13A;
- 6 (3) "Nurse" means a person who is licensed or holds the privilege to practice under the
7 provisions of this chapter as a registered nurse or as a licensed practical nurse;
- 8 (4) "Nursing process" means the investigative approach to nursing practice utilizing a
9 method of problem-solving by means of:
- 10 (a) Nursing diagnosis, a systematic investigation of a health concern, and an
11 analysis of the data collected in order to arrive at an identifiable problem; and
- 12 (b) Planning, implementation, and evaluation based on nationally accepted
13 standards of nursing practice;
- 14 (5) "Registered nurse" means one who is licensed or holds the privilege under the
15 provisions of this chapter to engage in registered nursing practice;
- 16 (6) "Registered nursing practice" means the performance of acts requiring substantial
17 specialized knowledge, judgment, and nursing skill based upon the principles of
18 psychological, biological, physical, and social sciences in the application of the
19 nursing process in:
- 20 (a) The care, counsel, and health teaching of the ill, injured, or infirm;
- 21 (b) The maintenance of health or prevention of illness of others;
- 22 (c) The administration of medication and treatment as prescribed by a physician,
23 physician assistant, dentist, or advanced practice registered nurse and as
24 further authorized or limited by the board, and which are consistent either
25 with American Nurses' Association Scope and Standards of Practice or with
26 standards of practice established by nationally accepted organizations of
27 registered nurses. Components of medication administration include but are

1 not limited to:

- 2 1. Preparing and giving medications in the prescribed dosage, route, and
3 frequency, including dispensing medications only as defined in
4 subsection (17)(b) of this section;
 - 5 2. Observing, recording, and reporting desired effects, untoward reactions,
6 and side effects of drug therapy;
 - 7 3. Intervening when emergency care is required as a result of drug therapy;
 - 8 4. Recognizing accepted prescribing limits and reporting deviations to the
9 prescribing individual;
 - 10 5. Recognizing drug incompatibilities and reporting interactions or
11 potential interactions to the prescribing individual; and
 - 12 6. Instructing an individual regarding medications;
- 13 (d) The supervision, teaching of, and delegation to other personnel in the
14 performance of activities relating to nursing care; and
- 15 (e) The performance of other nursing acts which are authorized or limited by the
16 board, and which are consistent either with American Nurses' Association
17 Standards of Practice or with Standards of Practice established by nationally
18 accepted organizations of registered nurses;
- 19 (7) "Advanced practice registered nurse" or "APRN" means a certified nurse
20 practitioner, certified registered nurse anesthetist, certified nurse midwife, or
21 clinical nurse specialist, who is licensed to engage in advance practice registered
22 nursing pursuant to KRS 314.042 and certified in at least one (1) population focus;
- 23 (8) "Advanced practice registered nursing" means the performance of additional acts by
24 registered nurses who have gained advanced clinical knowledge and skills through
25 an accredited education program that prepares the registered nurse for one (1) of the
26 four (4) APRN roles; who are certified by the American Nurses' Association or
27 other nationally established organizations or agencies recognized by the board to

1 certify registered nurses for advanced practice registered nursing as a certified nurse
2 practitioner, certified registered nurse anesthetist, certified nurse midwife, or
3 clinical nurse specialist; and who certified in at least one (1) population focus. The
4 additional acts shall, subject to approval of the board, include but not be limited to
5 prescribing treatment, drugs, devices, and ordering diagnostic tests. Advanced
6 practice registered nurses who engage in these additional acts shall be authorized to
7 issue prescriptions for and dispense nonscheduled legend drugs as defined in KRS
8 217.905 and to issue prescriptions for but not to dispense Schedules II through V
9 controlled substances ***described in or*** as classified ***pursuant to Section 2 of this Act***
10 ***or***~~in~~ KRS 218A.060,~~218A.070,~~ 218A.080,~~218A.090,~~ 218A.100,
11 ***and***~~218A.110,~~ 218A.120~~, and 218A.130,~~ under the conditions set forth in KRS
12 314.042 and regulations promulgated by the Kentucky Board of Nursing on or
13 before August 15, 2006.

- 14 (a) 1. Prescriptions issued by advanced practice registered nurses for Schedule
15 II controlled substances classified under KRS 218A.060, except
16 hydrocodone combination products as defined in KRS 218A.010, shall
17 be limited to a seventy-two (72) hour supply without any refill.
- 18 2. Prescriptions issued by advanced practice registered nurses for
19 hydrocodone combination products as defined in KRS 218A.010 shall
20 be limited to a thirty (30) day supply without any refill.
- 21 3. Prescriptions issued under this subsection for psychostimulants may be
22 written for a thirty (30) day supply only by an advanced practice
23 registered nurse certified in psychiatric-mental health nursing who is
24 providing services in a health facility as defined in KRS Chapter 216B
25 or in a regional services program for mental health or individuals with
26 an intellectual disability as defined in KRS Chapter 210.

- 27 (b) Prescriptions issued by advanced practice registered nurses for Schedule III

1 controlled substances classified under KRS 218A.080 shall be limited to a
2 thirty (30) day supply without any refill. Prescriptions issued by advanced
3 practice registered nurses for Schedules IV and V controlled substances
4 classified under KRS 218A.100 and 218A.120 shall be limited to the original
5 prescription and refills not to exceed a six (6) month supply.

6 (c) Limitations for specific controlled substances which are identified as having
7 the greatest potential for abuse or diversion, based on the best available
8 scientific and law enforcement evidence, shall be established in an
9 administrative regulation promulgated by the Kentucky Board of Nursing. The
10 regulation shall be based on recommendations from the Controlled Substances
11 Formulary Development Committee, which is hereby created. The committee
12 shall be composed of two (2) advanced practice registered nurses appointed by
13 the Kentucky Board of Nursing, one (1) of whom shall be designated as a
14 committee co-chair; two (2) physicians appointed by the Kentucky Board of
15 Medical Licensure, one (1) of whom shall be designated as a committee co-
16 chair; and one (1) pharmacist appointed by the Kentucky Board of Pharmacy.
17 The initial regulation shall be promulgated on or before August 15, 2006, and
18 shall be reviewed at least annually thereafter by the committee.

19 Nothing in this chapter shall be construed as requiring an advanced practice
20 registered nurse designated by the board as a certified registered nurse anesthetist to
21 obtain prescriptive authority pursuant to this chapter or any other provision of law
22 in order to deliver anesthesia care. The performance of these additional acts shall be
23 consistent with the certifying organization or agencies' scopes and standards of
24 practice recognized by the board by administrative regulation;

25 (9) "Licensed practical nurse" means one who is licensed or holds the privilege under
26 the provisions of this chapter to engage in licensed practical nursing practice;

27 (10) "Licensed practical nursing practice" means the performance of acts requiring

- 1 knowledge and skill such as are taught or acquired in approved schools for practical
2 nursing in:
- 3 (a) The observing and caring for the ill, injured, or infirm under the direction of a
4 registered nurse, advanced practice registered nurse, physician assistant,
5 licensed physician, or dentist;
- 6 (b) The giving of counsel and applying procedures to safeguard life and health, as
7 defined and authorized by the board;
- 8 (c) The administration of medication or treatment as authorized by a physician,
9 physician assistant, dentist, or advanced practice registered nurse and as
10 further authorized or limited by the board which is consistent with the
11 National Federation of Licensed Practical Nurses or with Standards of
12 Practice established by nationally accepted organizations of licensed practical
13 nurses;
- 14 (d) Teaching, supervising, and delegating except as limited by the board; and
- 15 (e) The performance of other nursing acts which are authorized or limited by the
16 board and which are consistent with the National Federation of Practical
17 Nurses' Standards of Practice or with Standards of Practice established by
18 nationally accepted organizations of licensed practical nurses;
- 19 (11) "School of nursing" means a nursing education program preparing persons for
20 licensure as a registered nurse or a practical nurse;
- 21 (12) "Continuing education" means offerings beyond the basic nursing program that
22 present specific content planned and evaluated to meet competency based
23 behavioral objectives which develop new skills and upgrade knowledge;
- 24 (13) "Nursing assistance" means the performance of delegated nursing acts by unlicensed
25 nursing personnel for compensation under supervision of a nurse;
- 26 (14) "Sexual assault nurse examiner" means a registered nurse who has completed the
27 required education and clinical experience and maintains a current credential from

1 the board as provided under KRS 314.142 to conduct forensic examinations of
2 victims of sexual offenses under the medical protocol issued by the Justice and
3 Public Safety Cabinet in consultation with the Sexual Assault Response Team
4 Advisory Committee pursuant to KRS 216B.400(4);

5 (15) "Competency" means the application of knowledge and skills in the utilization of
6 critical thinking, effective communication, interventions, and caring behaviors
7 consistent with the nurse's practice role within the context of the public's health,
8 safety, and welfare;

9 (16) "Credential" means a current license, registration, certificate, or other similar
10 authorization that is issued by the board;

11 (17) "Dispense" means:

12 (a) To receive and distribute noncontrolled legend drug samples from
13 pharmaceutical manufacturers to patients at no charge to the patient or any
14 other party; or

15 (b) To distribute noncontrolled legend drugs from a local, district, and
16 independent health department, subject to the direction of the appropriate
17 governing board of the individual health department;

18 (18) "Dialysis care" means a process by which dissolved substances are removed from a
19 patient's body by diffusion, osmosis, and convection from one (1) fluid
20 compartment to another across a semipermeable membrane;

21 (19) "Dialysis technician" means a person who is not a nurse, a physician assistant, or a
22 physician and who provides dialysis care in a licensed renal dialysis facility under
23 the direct, on-site supervision of a registered nurse or a physician;

24 (20) "Population focus" means the section of the population within which the advanced
25 practice registered nurse has targeted to practice. The categories of population foci
26 are:

27 (a) Family and individual across the lifespan;

- 1 (b) Adult gerontology;
- 2 (c) Neonatal;
- 3 (d) Pediatrics;
- 4 (e) Women's health and gender-related health; and
- 5 (f) Psychiatric mental health; and

6 (21) "Conviction" means but is not limited to:

- 7 (a) An unvacated adjudication of guilt;
- 8 (b) Pleading no contest or nolo contendere or entering an Alford plea; or
- 9 (c) Entering a guilty plea pursuant to a pretrial diversion order;

10 Regardless of whether the penalty is rebated, suspended, or probated.

11 ➔Section 7. The following KRS sections are repealed:

12 218A.030 Controlled substances -- How scheduled.

13 218A.050 Schedule I controlled substances.

14 218A.070 Schedule II controlled substances.

15 218A.090 Schedule III controlled substances.

16 218A.110 Schedule IV controlled substances.

17 218A.130 Schedule V controlled substances.